Dayton Misfeldt

2018

In 2018, Dayton Misfeldt earned a total compensation of $574.9K as Interim CEO at Sunesis Pharmaceuticals.

Compensation breakdown

Option Awards$524,939
Other$50,000
Total$574,939

Misfeldt received $524.9K in option awards, accounting for 91% of the total pay in 2018.

Misfeldt also received $50K in other compensation.

Rankings

In 2018, Dayton Misfeldt's compensation ranked 11,427th out of 14,244 executives tracked by ExecPay. In other words, Misfeldt earned more than 19.8% of executives.

ClassificationRankingPercentile
All
11,427
out of 14,244
20th
Division
Manufacturing
4,619
out of 5,765
20th
Major group
Chemicals And Allied Products
1,752
out of 2,128
18th
Industry group
Drugs
1,489
out of 1,817
18th
Industry
Pharmaceutical Preparations
1,143
out of 1,391
18th
Source: SEC filing on April 28, 2020.

Misfeldt's colleagues

We found one more compensation record of an executive who worked with Dayton Misfeldt at Sunesis Pharmaceuticals in 2018.

2018

William Quinn

Sunesis Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like